These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 6133821

  • 1. [Pharmacological studies on oxatomide: (6) Effect on the peripheral organs].
    Ohmori K, Ishii H, Shuto K, Nakamizo N.
    Nihon Yakurigaku Zasshi; 1983 Jan; 81(1):79-104. PubMed ID: 6133821
    [Abstract] [Full Text] [Related]

  • 2. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T, Ukai K, Masuda T, Nakagawa T, Kimura K, Fujii M, Wakatsuki K, Saeki M, Kasai H.
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [Abstract] [Full Text] [Related]

  • 3. [Pharmacological studies on oxatomide (KW-4354). (7) Antagonistic effects on chemical mediators].
    Ohmori K, Ishii H, Nito M, Shuto K, Nakamizo N.
    Nihon Yakurigaku Zasshi; 1983 May; 81(5):399-409. PubMed ID: 6138301
    [Abstract] [Full Text] [Related]

  • 4. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M, Yajima M, Nishimura T, Ikeda H, Nishimori T.
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K, Fujita S, Umezato M, Hosoki E, Toba Y, Kusunoki A, Shintani S.
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [Abstract] [Full Text] [Related]

  • 7. [General pharmacology of 6-amino-2-fluoromethyl-3-(o-tolyl)-4(3H)-quinazolinone (afloqualone), a new centrally acting muscle relaxant. II. Effects on the peripheral system (author's transl)].
    Ochiai T, Fukuchi I, Ego H, Yamamura M, Kudo Y, Ishida R.
    Nihon Yakurigaku Zasshi; 1981 Oct; 78(4):359-80. PubMed ID: 7327456
    [Abstract] [Full Text] [Related]

  • 8. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
    Andoh K, Kimura T, Saeki I, Tabata R, Yamazaki S, Eguchi I, Hanazuka M, Horii D, Munt PL, Davis AS.
    Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
    [Abstract] [Full Text] [Related]

  • 9. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T, Honbo T, Tokoro K, Kojimoto Y, Kodama R, Ohtsuka M, Shimomura K.
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Pharmacological actions of oxatomide (KW-4354). 3. Actions on experimental asthma and Schultz-Dale reaction].
    Ohmori K, Ishii H, Takei Y, Shuto K, Nakamizo N.
    Nihon Yakurigaku Zasshi; 1982 Dec; 80(6):481-93. PubMed ID: 6131021
    [Abstract] [Full Text] [Related]

  • 13. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y, Makino M, Usui C, Takasuna K, Kasai Y, Hirohashi M, Tamura K, Takayama S, Kojima H, Iizuka H.
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [Abstract] [Full Text] [Related]

  • 14. [Pharmacological studies on oxatomide. (5). Effect on the central and peripheral nervous systems].
    Ohmori K, Ishii H, Shuto K, Nakamizo N.
    Nihon Yakurigaku Zasshi; 1983 Mar; 81(3):245-66. PubMed ID: 6134657
    [Abstract] [Full Text] [Related]

  • 15. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
    Murata T, Murai T, Kanai T, Ogaki Y, Sanai K, Kanda H, Sato S, Kajikawa N, Umetsu T, Matsuura H.
    Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
    [Abstract] [Full Text] [Related]

  • 16. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y, Taira N, Fujitani B, Ito T, Kadokawa T.
    Arzneimittelforschung; 1986 Aug; 36(1):55-62. PubMed ID: 3513777
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamics.
    Yamamoto S, Takemori E, Hasegawa Y, Kuroda K, Nakao K, Inukai T, Sakonjyo H, Nishimura T, Nishimori T.
    Arzneimittelforschung; 1991 Sep; 41(9):913-23. PubMed ID: 1796919
    [Abstract] [Full Text] [Related]

  • 20. [Pharmacological studies on oxatomide (KW-4354): (2) Effect on the experimental models of the type 1-type 4 allergic reactions].
    Ohmori K, Ishii H, Hirayama T, Shuto K, Nakamizo N.
    Nihon Yakurigaku Zasshi; 1982 Sep; 80(3):261-70. PubMed ID: 6130033
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.